Full-length sequencing and baseline resistance-associated substitution of hepatitis C virus subtype 3b

Huang JieTing; Xu Ru; Liao Qiao; Wang Min; Dan ZhenGang; You QingZhu; Rong Xia; Fu YongShui

doi:10.3969/j.issn.1001-5256.2020.01.021

Volume 36 Issue 1

Jan. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(1): 94-97

PDF( 3648 KB)

Full-length sequencing and baseline resistance-associated substitution of hepatitis C virus subtype 3b

DOI: 10.3969/j.issn.1001-5256.2020.01.021

Guangzhou Blood Center

Research funding:

Received Date: 2019-09-02
Published Date: 2020-01-20

Abstract

Abstract

Objective To investigate the application of next-generation sequencing(NGS) in determining the full-length sequence and baseline resistance-associated substitution(RAS) of hepatitis C virus(HCV) subtype 3 b. Methods Nucleic acid was extracted from plasma of a HCV RNA-positive blood donor,and after sequence-independent amplification,a sequencing library was constructed and NGS was performed using Illumina Hiseq. Bioinformatics methods were used to analyze full-length HCV sequence,viral genotype,and baseline RAS to direct-acting antivirals(DAAs). Results A total of 8. 4 Gb data with more than 56 million reads were obtained. The full-length HCV sequence was obtained by bioinformatics analysis,with an average sequencing depth of 488 007 and a genotype of 3 b subtype. A total of 12 RASs were identified in HCV amino acid sequence,i. e.,Y56 H,Q80 K,Q80 R,and A156 G located in NS3,M28 G,Q/A30 G,Q/A30 K,L31 F,L31 M,and Y93 H located in NS5 A,and S282 T and V321 A located in NS5 B,among which Q/A30 K and L31 M located in NS5 A had high frequencies of 99. 16% and 98. 37%,respectively,while the other 10 RASs had low frequencies of < 0. 5%.Conclusion NGS can be used to determine the full-length sequence and genotype of HCV subtype 3 b and identify baseline RASs,which has great significance in the epidemiological study of HCV subtype 3 b and the development of DAA treatment regimens.
- hepacivirus,
- high-throughput nucleotide sequencing,
- genotype

FullText(HTML)

References(15)

References

[1] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1961-1979.

[2] THOMAS DL. Global control of hepatitis C:Where challenge meets opportunity[J]. Nat Med,2013,19(7):850-858.

[3] SMITH DB,BUKH J,KUIKEN C,et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:Updated criteria and genotype assignment web resource[J].Hepatology,2014,59(1):318-327.

[4] XU R,TONG W,GU L,et al. A panel of 16 full-length HCV genomes was characterized in China belonging to genotypes 1-6 including subtype 2f and two novel genotype 6 variants[J]. Infect Genet Evol,2013,20:225-229.

[5] MIAO ZQ. Application of direct-acting antiviral agents in treatment of hepatitis C[J]. Mod Pract Med,2018,30(3):284-286.(in Chinese)缪正秋．直接抗病毒药物治疗丙型肝炎的应用[J]．现代实用医学，2018,30(3):284-286.

[6] AN ZY,DING Y,DOU XG. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. J Clin Hepatol,2018,34(2):233-237.(in Chinese)安子英，丁洋，窦晓光．我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价[J]．临床肝胆病杂志，2018,34(2):233-237.

[7] QUAN M,XING HC. Effects of hepatitis C virus resistance associated variants on the efficacy of direct-acting antiviral agents[J/CD]. Chin J of Liver Diseases(Electronic Version),2018,10(3):32-36.(in Chinese)全敏，邢卉春．丙型肝炎病毒耐药相关变异对直接抗病毒药物疗效的影响[J/CD]．中国肝脏病杂志(电子版)，2018,10(3):32-36.

[8] KJELLIN M,KILENG H,AKABERI D,et al. Effect of the baseline Y93H resistance-associated substitution in HCV genotype3 for direct-acting antiviral treatment:Real-life experience from a multicenter study in Sweden and Norway[J]. Scand J Gastroenterol,2019,54(8):1042-1050.

[9] NG TF,KONDOV NO,DENG X,et al. A metagenomics and case-control study to identify viruses associated with bovine respiratory disease[J]. J Virol,2015,89(10):5340-5349.

[10] THOMSON E,IP CL,BADHAN A,et al. Comparison of nextgeneration sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes[J]. J Clin Microbiol,2016,54(10):2470-2484.

[11] RONG X,XU R,XIONG H,et al. Increased prevalence of hepatitis C virus subtype 6a in China:A comparison between2004-2007 and 2008-2011[J]. Arch Virol,2014,159(12):3231-3237.

[12] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016[J]. J Hepatol,2017,66(1):153-194.

[13] PERALES C,CHEN Q,SORIA ME,et al. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15%may be clinically significant[J]. Infect Drug Resist,2018,11:2207-2210.

[14] KAI Y,HIKITA H,MORISHITA N,et al. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment[J]. Sci Rep,2017,7:41660.

[15] NAKANO K,SHIROMA A,SHIMOJI M,et al. Advantages of genome sequencing by long-read sequencer using SMRT technology in medical area[J]. Hum Cell,2017,30(3):149-161.

Relative Articles

[1]	Jun GAO, Huan CHEN, Yan LIU, Feng ZHANG, Yuzheng ZHUGE. Effect of interleukin-22 on hepatic stellate cell activation and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2229-2237. doi: 10.12449/JCH241116
[2]	Yekai ZONG, Jiangkai LIU. The physiological and pathological role of amyloid protein in the liver[J]. Journal of Clinical Hepatology, 2023, 39(11): 2730-2737. doi: 10.3969/j.issn.1001-5256.2023.11.031
[3]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[4]	Xiaolu ZHAO, Chunyan ZHANG, Xiaoyang GAO, Yuehong MA. Mechanism of action of the Hippo/YAP pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1654-1657. doi: 10.3969/j.issn.1001-5256.2022.07.037
[5]	Xin LUO, Ying QU, Xiaobo CAI, Lungen LU. Effects of antiviral therapy on the reversal of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2596-2598. doi: 10.3969/j.issn.1001-5256.2022.11.032
[6]	Wenzheng YOU, Wanlei REN, Shiying XUAN, Doudou HU. Association between intrahepatic bile duct alterations and liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 187-190. doi: 10.3969/j.issn.1001-5256.2022.01.032
[7]	Fan Chang, Wu FuRong, Zhang JiaFu, Jiang Hui. Role of pyroptosis in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1138-1140. doi: 10.3969/j.issn.1001-5256.2020.05.042
[8]	YANG Jing, GAO Hong, ZHAO YaoWei, WANG Rui. Role of liver sinusoidal endothelial cells in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2601-2605. doi: 10.3969/j.issn.1001-5256.2020.11.046
[9]	Geng WenJing, Liu Hui, Ding HuiGuo. Recent advances in drug-induced liver injury: Potential mechanisms, pathological features, and biomarkers[J]. Journal of Clinical Hepatology, 2019, 35(4): 925-929. doi: 10.3969/j.issn.1001-5256.2019.04.049
[10]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[11]	Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
[12]	Wang BingQiong, Sun YaMeng, You Hong, Shao Chen, Wang TaiLing. Pathological assessment of liver fibrosis regression[J]. Journal of Clinical Hepatology, 2017, 33(3): 435-437. doi: 10.3969/j.issn.1001-5256.2017.03.007
[13]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[14]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[15]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[16]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[17]	Wang WeiBin, Zhu YouFu. A brief discussion on pathogenesis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 805-809. doi: 10.3969/j.issn.1001-5256.2013.11.002
[18]	Sha XiuJuan, Xin GuiJie, Jin MeiShan, Chi TouMei, Niu JunQi. Pay much attention to the clinical application of pathological examination of liver biopsy in the diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(3): 223-226.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	翟飞，闫菊，何嘉宾，张庆勇，吴燕. 开腹联合肝脏离断和门静脉结扎二步肝切除术治疗原发性肝癌疗效及对患者肝功能指标、术后生存情况的影响. 临床和实验医学杂志. 2023(04): 375-379 .
2.	尚敏杰，张军港，顾宗庭，魏芳强，陶然，吴国清，文阳，沈坚，唐雨琪. 免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效. 中华消化外科杂志. 2023(02): 281-285 .
3.	郭佳胤，徐杰，刘作金. 腹腔镜下ALPPS右半肝切除一例（附视频）. 中华肝脏外科手术学电子杂志. 2023(03): 345-347 .
4.	杨雄威，高晓杰，覃日利，张新晨. ALPPS临床应用及术式改良. 中华肝脏外科手术学电子杂志. 2022(04): 347-350 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1327) PDF downloads(225)

Full-length sequencing and baseline resistance-associated substitution of hepatitis C virus subtype 3b

DOI: 10.3969/j.issn.1001-5256.2020.01.021